Pregnancy and lactation labels

For decades, FDA drug labels used pregnancy letter categories-A, B, C, D, and X-to communicate risk. In 2015, the Pregnancy and Lactation Labeling Rule changed that system. The letters are gone, replaced by narrative sections that aim to give clinicians and patients more useful, context-rich information.

Today's labels are organized into three subsections. The Pregnancy subsection includes a risk summary, clinical considerations, and a summary of available data. The Lactation subsection discusses whether the drug is present in human milk and what is known about effects on the breastfed infant. The Females and Males of Reproductive Potential subsection covers pregnancy testing, contraception, and infertility.

For newer peptide medicines, especially the GLP-1 receptor agonists and dual GIP/GLP-1 agonists, these sections often describe limited human pregnancy data. Animal studies may be summarized, but animal findings do not always predict human risk. The labels typically advise stopping the medication at least two months before a planned pregnancy and discontinuing it as soon as pregnancy is recognized.

Breastfeeding data are even sparser. Most labels state that it is not known whether the drug is present in human milk or what effect it might have on a breastfed infant. Because of that uncertainty, clinicians usually weigh the benefits of breastfeeding against the mother's clinical need for the medication.

Reading the label directly matters because recommendations can change as new data become available. A blog post or social clip may quote an older version. The FDA-approved label is the authoritative source, and it is updated periodically.

If you are pregnant, planning pregnancy, or breastfeeding, bring the current label to your clinician and ask how it applies to your specific situation. The label gives the framework; the clinician helps apply it.